NewAmsterdam Pharma Company N.V. Shares Outstanding (Cover Page)
NewAmsterdam Pharma Company N.V. (NAMS) had Shares Outstanding (Cover Page) of 119.54 million shares as of 2026-08-03, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Cover Page
dei:EntityCommonStockSharesOutstanding · last filed 2026-08-05
- 2026-08-03: Entity Common Stock, Shares Outstanding 119.54M shares.
- 2026-04-29: Entity Common Stock, Shares Outstanding 116.90M shares.
- 2026-02-05: Entity Common Stock, Shares Outstanding 114.98M shares.
- 2025-10-31: Entity Common Stock, Shares Outstanding 113.39M shares.
| Period end | Entity Common Stock, Shares Outstanding |
|---|---|
| 2026-08-03 | 119.54M shares 10-Q · filed 2026-08-05 |
| 2026-04-29 | 116.90M shares 10-Q · filed 2026-05-07 |
| 2026-02-05 | 114.98M shares 10-K · filed 2026-02-18 |
| 2025-10-31 | 113.39M shares 10-Q · filed 2025-11-05 |
| 2025-07-31 | 112.63M shares 10-Q · filed 2025-08-06 |
| 2025-05-02 | 112.27M shares 10-Q · filed 2025-05-08 |
| 2025-02-18 | 109.82M shares 10-K · filed 2025-02-26 |
| 2024-10-31 | 92.39M shares 10-Q · filed 2024-11-06 |
| 2024-08-02 | 90.02M shares 10-Q · filed 2024-08-07 |
| 2024-05-03 | 89.98M shares 10-Q · filed 2024-05-08 |
| 2024-02-16 | 89.27M shares 10-K · filed 2024-02-28 |
| 2022-12-31 | 81.56M shares 20-F/A · filed 2024-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |